Hematology · Oncology · Internal Medicine · June 2026
A comprehensive, medically reviewed reference on Anadrol-50 (oxymetholone) — covering its pharmacology, FDA-approved indication for anemias caused by deficient red cell production, how it compares to other treatments for bone marrow failure anemias, critical safety information, and legal access for patients in the United States and internationally.
Medically reviewed by a Licensed Clinical Pharmacist | Last updated: June 2026
| Generic Name | Oxymetholone |
| Brand Name | Anadrol-50 |
| Drug Class | Synthetic anabolic androgenic steroid (AAS), 17-alpha-alkylated testosterone derivative |
| FDA Approval | 1976, for anemias due to deficient red cell production |
| DEA Schedule | Schedule III controlled substance |
| Available Dose | 50 mg tablets (scored) |
| Standard Adult Dose | 1–5 mg/kg per day, once daily or in divided doses |
| Time to Response | Response may take 3 to 6 months of continued therapy to become apparent |
| Half-Life | Approximately 9 hours |
| Mechanism | Stimulates erythropoietin production and has a direct erythropoietic effect on bone marrow |
| Boxed Warning | Hepatotoxicity, including peliosis hepatis and hepatic neoplasms — risk generally considered higher than with other oral anabolic steroids |
| Generic Available | Yes — oxymetholone is available in generic form |
Anadrol-50 is the brand name for oxymetholone, a synthetic anabolic androgenic steroid approved by the U.S. Food and Drug Administration in 1976 for the treatment of anemias caused by deficient red blood cell production, including aplastic anemia, congenital aplastic anemia (Fanconi's anemia), myelofibrosis, and anemias resulting from the administration of myelotoxic drugs. Its primary clinical value lies in its ability to stimulate red blood cell production in patients whose bone marrow is not generating enough red cells on its own.
Oxymetholone has historically played an important role in the management of bone marrow failure anemias, particularly before the availability of recombinant erythropoietin-stimulating agents and modern immunosuppressive and transplant-based therapies. It remains a relevant option today, particularly for patients who have not responded adequately to first-line treatments or for whom those options are not accessible or appropriate, and is generally managed by a hematologist given the complexity of the underlying conditions it treats.
Oxymetholone is available in generic form and is classified as a Schedule III controlled substance in the United States, reflecting both its legitimate and significant medical utility in treating serious anemias and its recognized potential for non-medical misuse, particularly in bodybuilding and athletic contexts due to its pronounced effect on lean mass and water retention — a use that falls entirely outside its approved medical indication and carries serious health risks, including a generally higher hepatotoxicity burden than other oral anabolic steroids.
Oxymetholone stimulates erythropoiesis — the production of red blood cells — through a combination of mechanisms. It is believed to increase the production of erythropoietin, the hormone primarily produced by the kidneys that signals bone marrow to produce red blood cells, and it may also act directly on erythroid progenitor cells in the bone marrow, enhancing their sensitivity to erythropoietin and stimulating red cell production even in some patients whose bone marrow is significantly compromised.
Like other anabolic androgenic steroids, oxymetholone also binds androgen receptors in muscle and other tissues, producing anabolic effects on protein synthesis and nitrogen retention, along with androgenic effects. However, its FDA-approved clinical use centers specifically on its erythropoietic effect in bone marrow failure anemias rather than on general anabolic or weight-restoration goals.
Response to oxymetholone in anemia treatment is often gradual, with meaningful improvement in red blood cell counts sometimes taking 3 to 6 months of continued therapy to become fully apparent, reflecting the time required for stimulated bone marrow activity to translate into a measurable increase in circulating red blood cells. As a 17-alpha-alkylated steroid, oxymetholone is orally bioavailable, but this same structural feature is associated with a hepatotoxicity risk that is a defining safety consideration throughout treatment.
| Feature | Oxymetholone (Anadrol-50) | Epoetin Alfa (Recombinant EPO) | Danazol | Bone Marrow / Stem Cell Transplant |
|---|---|---|---|---|
| Drug Class | Anabolic androgenic steroid | Recombinant erythropoietin | Synthetic androgen (attenuated) | Not a drug — cellular therapy |
| Route | Oral | Injectable | Oral | Procedural |
| Primary Role Today | Second-line or adjunct for marrow failure anemias | First-line for many chronic anemias of underproduction | Used in some marrow failure and hematologic conditions | Potentially curative for eligible aplastic anemia patients |
| Onset of Response | 3–6 months | Weeks to a few months | Variable, often months | Variable, procedure-dependent |
| Hepatotoxicity Risk | Present (boxed warning), generally higher among oral steroids | Not applicable | Present, generally lower than oxymetholone | Not applicable |
| DEA Schedule | Schedule III | Not controlled | Not controlled | Not applicable |
Modern hematology practice generally favors recombinant erythropoietin-stimulating agents, immunosuppressive therapy, or bone marrow and stem cell transplantation as first-line approaches for many bone marrow failure anemias, given their more favorable safety profiles or curative potential in eligible patients. Oxymetholone remains clinically relevant for patients who have not responded to these approaches, who are not candidates for transplant, or in specific clinical circumstances where its particular erythropoietic mechanism offers benefit. This decision is made by a hematologist based on the specific anemia subtype, prior treatment response, and overall clinical picture.
Anadrol-50 is FDA-approved for the treatment of anemias caused by deficient red blood cell production, including acquired and congenital aplastic anemia, myelofibrosis (a bone marrow disorder that impairs normal blood cell production), and anemias caused by the administration of myelotoxic drugs (medications that damage bone marrow function, such as certain chemotherapy agents). Response rates vary considerably by underlying diagnosis, with some patients experiencing meaningful improvement in red blood cell counts and reduced transfusion requirements, while others show a more limited response, reinforcing the importance of ongoing hematology follow-up throughout treatment to reassess benefit versus risk.
Anadrol-50 is available as a 50 mg scored tablet. Dosing is individualized based on the patient's weight, the underlying anemia diagnosis, and response to treatment, and is generally managed by a hematologist.
| Initial Dose | Approximately 1–5 mg per kilogram of body weight per day, given once daily or in divided doses. The effective dose varies considerably between individuals and diagnoses. |
| Trial Duration Before Assessing Response | A minimum trial of 3 to 6 months is generally recommended before concluding the medication is not effective for a given patient, given the gradual onset of erythropoietic response. |
| Maintenance | Once a response is achieved, the dose may be reduced to the minimum effective amount that maintains the improved red blood cell count, under close hematology supervision. |
| Pediatric Use | Used under specialist (pediatric hematology) supervision with close monitoring of growth and bone age, given the risk of accelerated epiphyseal maturation. |
| Hepatic Impairment | Use requires extreme caution and close monitoring given oxymetholone's hepatic metabolism and hepatotoxicity risk; may not be appropriate in significant pre-existing liver disease. |
Because oxymetholone's erythropoietic effect can take several months to become apparent, treatment is generally continued for a defined trial period with regular blood count monitoring before efficacy is judged. Dose changes and decisions to continue or discontinue therapy should always be made in close consultation with a hematologist, balancing the potential hematologic benefit against oxymetholone's recognized hepatic and androgenic risks.
Anadrol-50 is generally taken once daily or in divided doses as directed by the prescribing hematologist, with or without food. The scored tablet may be split if a specific partial dose has been directed.
Regular blood counts, including hemoglobin and hematocrit, are monitored throughout treatment to assess response and guide dose adjustments. Liver function tests are also monitored on a regular schedule given the hepatotoxicity risk associated with this medication, and patients should attend all scheduled laboratory appointments for the duration of treatment.
Because the erythropoietic response to oxymetholone develops gradually, patients should not expect an immediate change in symptoms such as fatigue or shortness of breath, and should continue treatment as directed while awaiting the results of periodic blood count monitoring, which is the primary way response is assessed.
Oxymetholone's side effect profile reflects its androgenic activity, its effect on fluid balance, and its hepatic metabolism, and is generally more pronounced than that of oxandrolone given oxymetholone's comparatively higher potency and less favorable anabolic-to-androgenic ratio.
Fluid retention and edema are common and can be pronounced, sometimes requiring dose adjustment or additional management. Acne and other androgen-related skin changes are frequently reported. Changes in libido and, in men, gynecomastia may occur. Nausea and gastrointestinal discomfort are also reported by some patients, particularly early in treatment.
In women, virilizing effects — including voice deepening, increased facial or body hair, clitoral enlargement, and menstrual changes — are a recognized and often more pronounced risk with oxymetholone than with lower-potency anabolic agents, and may not fully reverse if the medication is continued after early signs appear. In men, suppression of natural testosterone production and, in some cases, priapism (a prolonged, painful erection) have been reported and require prompt medical attention if they occur.
Anadrol-50 carries an FDA boxed warning for hepatotoxicity that is generally considered more pronounced than that of other oral anabolic steroids, reflecting both its 17-alpha-alkylated structure and the doses used clinically. Reported hepatic effects include peliosis hepatis (blood-filled cysts within the liver that can rupture and cause life-threatening hemorrhage), cholestatic hepatitis with jaundice, and, with prolonged use, benign and malignant hepatic tumors, including hepatocellular carcinoma. These changes may occur without early warning symptoms or abnormal screening tests, and some hepatic effects have been reported to persist or progress even after the medication is stopped. Regular liver function monitoring throughout treatment is essential, and any new abdominal pain, jaundice, dark urine, or unusual fatigue requires prompt medical evaluation.
Oxymetholone can significantly lower HDL cholesterol and raise LDL cholesterol, an adverse lipid shift that may increase cardiovascular risk, particularly with extended treatment courses. Periodic lipid monitoring is standard during therapy.
In pediatric patients, oxymetholone can accelerate bone maturation without a proportional increase in height, potentially reducing final adult height if growth plates close prematurely. Regular bone age assessment is standard practice in children receiving this medication.
Androgens, including oxymetholone, may stimulate the growth of existing prostate tissue and are contraindicated in men with known or suspected prostate cancer. Periodic prostate evaluation is advisable during extended treatment in older men.
Oxymetholone's pronounced anabolic effect on lean mass and water retention has made it one of the anabolic steroids more frequently diverted for non-medical bodybuilding and performance use, which is part of the basis for its Schedule III controlled substance status. Use outside a valid prescription and a genuine hematologic diagnosis carries the same hepatic, cardiovascular, and androgenic risks described in this guide — often magnified by higher, unsupervised doses — and is not a use this guide supports or provides direction for.
| Interaction | Mechanism | Clinical Consequence | Management |
|---|---|---|---|
| Warfarin and other anticoagulants | Oxymetholone potentiates anticoagulant effect | Significant increase in bleeding risk and INR elevation | Anticoagulant dose reduction and closer INR monitoring are typically required. |
| Insulin and oral antidiabetic medications | Anabolic steroids may improve glucose tolerance | Reduced insulin or antidiabetic requirement, risk of hypoglycemia if not adjusted | Monitor blood glucose closely; medication doses may need reduction under physician guidance. |
| Corticosteroids and other fluid-retaining medications | Additive fluid retention | Increased risk of edema, particularly relevant given oxymetholone's own fluid-retaining effect | Monitor for edema, particularly in patients with cardiac or renal impairment. |
| Other hepatotoxic medications | Additive hepatic burden | Increased risk of liver injury | Disclose all medications; more frequent liver monitoring may be warranted. |
Severe abdominal pain, yellowing of the skin or eyes, dark urine, or an erection lasting more than four hours during Anadrol-50 treatment represent medical emergencies. Seek immediate medical evaluation.
Known or suspected prostate cancer, or male breast cancer: Contraindicated given the risk of androgen-sensitive tumor stimulation.
Pregnancy: Contraindicated due to the risk of virilization of a female fetus.
Significant hepatic disease: Requires extreme caution given oxymetholone's hepatic metabolism and pronounced hepatotoxicity risk; may be inappropriate in significant pre-existing liver impairment.
Severe cardiac or renal disease: Use requires caution given the fluid retention associated with this medication.
Known hypersensitivity: Contraindicated in patients with a prior hypersensitivity reaction to oxymetholone or its components.
Hypercalcemia: Requires close monitoring, particularly in patients with breast cancer and bone metastases.
Pediatric patients: Requires specialist hematology and endocrinology supervision given the risk of accelerated bone maturation and effects on final adult height.
Commit to the full monitoring schedule. Given oxymetholone's pronounced hepatotoxicity risk and the months-long timeline typically needed to assess erythropoietic response, consistent attendance at blood count and liver function monitoring appointments is essential rather than optional.
Report any signs of virilization promptly if you are a woman taking this medication, so the treatment plan can be reassessed before effects progress.
Seek immediate care for any erection lasting more than four hours, severe abdominal pain, or yellowing of the skin or eyes, all of which represent medical emergencies during treatment.
Give treatment adequate time before judging its effectiveness. The erythropoietic response to oxymetholone often takes 3 to 6 months to become fully apparent; discuss any concerns about response with your hematologist rather than discontinuing prematurely.
Never use oxymetholone obtained outside a valid prescription or a genuine hematologic diagnosis; doing so removes the specialist monitoring that meaningfully reduces this medication's most serious risks.
Store at room temperature (20–25°C / 68–77°F), away from moisture, heat, and light, and out of reach of children. As a Schedule III controlled substance, Anadrol-50 should never be shared.
In the United States, Anadrol-50 is a prescription medication classified as a Schedule III controlled substance, available from any licensed pharmacy following evaluation and diagnosis by a physician, typically a hematologist, given the serious underlying conditions it is used to treat. Generic oxymetholone is available and is generally prescribed alongside a structured monitoring plan including regular blood counts and liver function testing.
Given the seriousness of the conditions oxymetholone treats and its controlled substance status, prescribing is closely tied to a documented anemia diagnosis and ongoing hematology follow-up rather than a standalone, self-directed treatment decision.
Internationally, oxymetholone is a controlled or prescription-only medication in most major healthcare markets. The same standard for legitimate pharmacy sourcing applies universally: a mandatory prescription requirement tied to a genuine medical diagnosis, a verifiable pharmacy license, transparent pricing, and accountable dispensing records. As one of the more potent and frequently diverted oral anabolic steroids, oxymetholone sourced from unlicensed vendors carries substantial risk, including counterfeit, mislabeled, or contaminated products.
My Online Med Shop provides genuine, verified Anadrol-50 (oxymetholone) sourced exclusively from verified pharmaceutical manufacturers, dispensed strictly against a valid prescription and documented medical diagnosis, with secure encrypted checkout, discreet packaging, and 24/7 customer support available for every order.
Anadrol-50 (oxymetholone) is FDA-approved for anemias caused by deficient red blood cell production, including aplastic anemia, congenital aplastic anemia, myelofibrosis, and anemias caused by drugs that damage bone marrow function. It works by stimulating the bone marrow to produce more red blood cells, typically under the care of a hematologist.
Response can be gradual, with meaningful improvement in red blood cell counts sometimes taking 3 to 6 months of continued treatment to become apparent. Regular blood count monitoring during this period is how response is tracked, and premature discontinuation before this window has elapsed may not reflect a true lack of effectiveness.
Oxymetholone is a 17-alpha-alkylated steroid used at doses that, combined with its particular hepatic metabolism, have been associated with a generally higher reported rate of hepatotoxic effects — including peliosis hepatis and hepatic tumors — compared to some other oral anabolic agents. This is reflected in its FDA boxed warning and the standard practice of regular liver function monitoring throughout treatment.
Yes, though its role has narrowed. Recombinant erythropoietin-stimulating agents, immunosuppressive therapy, and stem cell transplantation are generally preferred first-line approaches for many bone marrow failure anemias today. Oxymetholone remains a relevant option for patients who have not responded to these treatments, are not candidates for them, or in specific clinical situations where a hematologist determines it offers meaningful benefit.
Anadrol-50 can be used in women for its approved anemia indication, but virilizing effects — including voice deepening, facial or body hair growth, and clitoral enlargement — are a recognized and often more pronounced risk with this medication than with lower-potency anabolic agents. Any early signs of virilization should be reported to the prescribing hematologist promptly so the treatment plan can be reassessed.
Oxymetholone is chemically an anabolic androgenic steroid, and its pronounced effect on lean mass and water retention has made it one of the agents more frequently diverted for non-medical bodybuilding use, which contributes to its Schedule III status. Its FDA-approved medical use is specifically for treating serious anemias under hematology supervision with defined dosing and monitoring — a fundamentally different context from unsupervised non-medical use, which carries the same (and often magnified) hepatic and androgenic risks described in this guide.
Regular blood counts (hemoglobin and hematocrit) are used to track the medication's erythropoietic effect, and liver function tests are monitored regularly given the pronounced hepatotoxicity risk associated with this medication. Lipid panels and, in pediatric patients, bone age assessments are also part of standard monitoring.
Anadrol-50 (oxymetholone) holds a long-established, if increasingly specialized, role in the treatment of anemias caused by deficient red blood cell production, particularly aplastic anemia and related bone marrow failure conditions. Its ability to stimulate erythropoiesis has provided meaningful benefit for patients, particularly those who have not responded to newer first-line therapies such as recombinant erythropoietin or who are not candidates for stem cell transplantation.
As a 17-alpha-alkylated anabolic steroid with a hepatotoxicity profile generally considered more pronounced than some other oral agents in its class, Anadrol-50 requires close, sustained hematology supervision, regular laboratory monitoring, and patience given the months-long timeline often needed to assess its erythropoietic benefit.
Within the parameters of a valid prescription, a genuine hematologic diagnosis, consistent specialist monitoring, and verified pharmaceutical sourcing, Anadrol-50 remains a clinically meaningful option for a defined group of patients with serious anemias, distinct from and not a substitute for its non-medical, unsupervised use in other contexts.
Buy Oxycodone Online USA: Uses, Dosage & Safety Guide 2026
Buy Oxandrolone Online USA: Uses, Dosage & Safety Guide 2026
Buy Anadrol-50 Online USA: Uses, Dosage & Safety Guide 2026
Buy Escitalopram Online USA: Uses, Dosage & Safety Guide 2026